Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.63 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.62 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511533 | 0.94 | FFAR1 (0.59) | NR4A2FFAR1CYP4F2CYP4A11MAOB | |
| SCHEMBL3908596 | 0.91 | CFD (0.66) | NR4A2FFAR1MAOBLTB4RLTB4R2 | |
| SCHEMBL15297882 | 0.89 | MAOB (0.63) | NR4A2FFAR1CYP4F2CYP4A11MAOB | |
| SCHEMBL5090803 | 0.89 | NR4A2 (0.68) | NR4A2FFAR1MAOBLTB4RLTB4R2 | |
| SCHEMBL14514248 | 0.89 | FFAR1 (0.57) | NR4A2FFAR1CYP4F2CYP4A11MAOB | |
| SCHEMBL14032965 | 0.89 | LCK (0.66) | NR4A2FFAR1CYP4F2CYP4A11MAOB | |
| SCHEMBL9080535 | 0.88 | MRGPRX4 (0.60) | NR4A2FFAR1MAOBLTB4RLTB4R2 | |
| SCHEMBL9205498 | 0.88 | LTB4R (0.68) | NR4A2FFAR1CYP4F2CYP4A11MAOB | |
| SCHEMBL2957881 | 0.88 | MEN1 (0.67) | NR4A2FFAR1CYP4F2CYP4A11MAOB | |
| SCHEMBL5017852 | 0.87 | PLA2G4B (0.56) | NR4A2FFAR1CYP4F2CYP4A11MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | claimed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | claimed |
| CN-101969773-B | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP. (US) | 2015-08-19 | — | — | CN | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| CN-101969773-A | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2011-02-09 | — | — | CN | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| JP-51133246-A | — | — | None | — | — | JP | disclosed |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-0249245-A2 | Antihypertensive dihydropyridine derivatives | LABORATOIRES SYNTEX S.A. (FR) | 1987-12-16 | — | — | EP | disclosed |
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4611078-A | ANTIDEPRESSANT INTERMEDIATES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | disclosed |
| JP-S51133246-A | PROCESS FOR PREPARING 3- BENZYLOXYPHENYLACETIC ACIDS | GRELAN PHARMACEUT CO LTD | 1976-11-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | NR4A2 910/4885FFAR1 710/4885CYP4F2 2990/4885 |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | NR4A2 159/4885FFAR1 3895/4885CYP4F2 2577/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | NR4A2 1494/4885FFAR1 5/4885CYP4F2 392/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | NR4A2 159/4885FFAR1 3895/4885CYP4F2 2577/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | NR4A2 1952/4885FFAR1 513/4885CYP4F2 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.